COMP <GO>
CI vs ELV // EV/EBITDA & P/E VALUATION
The Cigna Group (NYSE) VS. Elevance Health Inc. (NYSE) • 15-METRIC TALLY: CI 6
— ELV 8
▲ EV/EBITDA & P/E VALUATION LEADER: CI
LAST: $298.23 (-0.06%) • MKT CAP: $78.85B
valuation
6.1x
LAST: $420.07 (-0.46%) • MKT CAP: $91.18B
valuation
13.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CI VS. ELV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CI | ELV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.80% | 89.40% | -67.60 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 8.70% | +0.10 | CI | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.1x | 13.8x | -7.70 | CI | /valuation <GO> |
| Free Cash Flow Yield | -3.51% | 3.48% | -6.99 | ELV | /fcf-yield <GO> |
| Operating Margin | 3.30% | 3.60% | -0.30 | ELV | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 2.80% | -0.60 | ELV | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 12.50% | -1.30 | ELV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.04% | 1.68% | +0.36 | CI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.70 | 3.17 | -0.47 | ELV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ELV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 52.0 | +3.80 | CI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.07 | +0.05 | CI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 13.5x | -1.20 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.85B | $91.18B | -$12.33B | ELV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CI REV | ELV REV | CI GROSS % | ELV GROSS % | CI FCF | ELV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $274.90B | $199.13B | 21.8% | 89.4% | -$2.77B | $3.17B |
| FY 2024 | $247.12B | $177.01B | 26.1% | 88.8% | -$757.4M | $4.55B |
| FY 2023 | $195.26B | $171.34B | — | — | $3.03B | $350.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CI // BETA 1.12
ELV // BETA 1.07